FULC Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025

3 days ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025

15 days ago - By: Zacks Investment Research - Mentions: ALKS AGIO CRMD

AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results

17 days ago - By: Benzinga - Mentions: NICE HD HP HTHT ...

Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

a month ago - By: Benzinga - Mentions: CGO ROL ESRT NNBR ...

Earnings Scheduled For October 29, 2025

a month ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

a month ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

a month ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025

a month ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025

a month ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET

a month ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET

2 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025

2 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025

2 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics to Present at Upcoming Investor Meetings

3 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics to Present at Upcoming Investor Meetings

4 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025

4 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025

4 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

4 months ago - By: Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

4 months ago - By: Fulcrum Therapeutics, Inc.

FULCRUM THERAPEUTICS INC (FULC) Stock News

FULC Latest News, Press Relases and Analysis

Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025

Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025

AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results

Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Earnings Scheduled For October 29, 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025

Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET

Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET

Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025

Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fulcrum Therapeutics to Present at Upcoming Investor Meetings

Fulcrum Therapeutics to Present at Upcoming Investor Meetings

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025

Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease